”We’re Past the Inflection Point,” as ”Massive Change” Hits Breast Cancer Care
Get every episode summarized
Each time Oncology News Central Peer-Spectives publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
About this episode
From ASCO 2024.
When it comes to the use of antibody-drug conjugates (ADCs) in breast cancer care, "we're past the inflection point," says Hope S. Rugo, MD, a breast cancer oncologist and professor of medicine in the Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
Get every episode summarized
Each time Oncology News Central Peer-Spectives publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from Oncology News Central Peer-Spectives
Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clini...
Oncology News Central Peer-Spectives
Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care
Oncology News Central Peer-Spectives
Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC
Oncology News Central Peer-Spectives
“Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Trea...
Oncology News Central Peer-Spectives